EGFR and non-small cell lung carcinoma: EGFR (epidermal growth factor receptor) gene mutations are the most common targetable driver mutations seen in up to 32.3% of non-small-cell lung cancer (NSCLC) patients, and targeted therapies that improve survival highlight the need for early molecular diagnosis [4,5].